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Table S1 . Target compounds by therapeutic groups, used surrogates and optimized chromatographic and ESI-MS/MS parameters 









































































Surrogate EF Rs 




























































  rac-Ketoprofen-13C-d3 







[M+H]+ 213.21 40-14 - - 8.27 - - - - 































[M+H]+ 170.20 56-20 132.54 56-14 




24.08 19.70 Clenbuterol-d9 E2 




































[M+H]+ 185.11 34-14 170.33 28-24 7.94 10.11 
rac-
Naproxen-d3 - - 






































































[M+H]+ 43.98 34-10 148.11 34-10 
38.23 14.97 Fluoxetine-d5 (S+) 















[M+H]+ 153.16 26-8 
- - 38.23 - - - - 
   (R
-)
 
- - 41.75 - - - - 
5 
rac-
Norfluoxetine      





























[M+H]+ 134.09 18-6 














rac-Ofloxacin                          






































[M+H]+ 318.07 48-20 261.09 42-30 - - 
rac-
Ofloxacin-d8 - - 
  rac-Ofloxacin-d8 - -  - 370.27 [M+H]+ 265.14 54-32 - - - - - - - 











































  rac-Flumequine-13C3 






































































[M+H]+ 145.1 38-30 190.1 38-16 
39.39 1.44 Atenolol-d7 (S-) 






42.75 1.43 Atenolol-d7 (R+) 
  





[M+H]+ 145.09 44-30 
- - 39.23 - - - - 
   (R
+)
 
- - 42.59 - - - - 
9 
rac-Sotalol                               






































[M+H]+ 133.21 30-28 213.10 30-16 
32.68 1.43 Sotalol-d7 E1 





36.51 1.39 Sotalol-d7 E2 
  




[M+H]+ 134.20 32-36 
- - 32.6 - - - - 
   E2
 
- - 36.36 - - - - 
1
0 
rac-Metoprolol                      








































[M+H]+ 116.09 42-20 121.1 42-22 












[M+H]+ 123.12 44-20 

















rac-Propranolol                     







































[M+H]+ 116.09 42-16 183.09 42-18 
28.92 1.90 Propranolol-d7 (S-) 















[M+H]+ 123.18 42-18 
- - 28.92 - - - - 
   (R
+)
 




propranolol         







































[M+H]+ 116.39 40-20 173.34 40-20 








rac-Timolol                              



































[M+H]+ 261.13 38-16 244.09 38-22 







- - Timolol-d5 (R+) 
  





[M+H]+ 266.19 40-18 
- - 30.52 - - - - 
   (R
+)
 







rac-Betaxolol                          






































[M+H]+ 116.09 44-24 121.04 44-30 




26.56 3.31 Pindolol-d7 E2 
1
5 
rac-Carazolol                          






































[M+H]+ 116.09 44-24 222.11 44-18 




29.24 5.31 Metoprolol-d7 E2 
1
6 
rac-Pindolol                            








































[M+H]+ 116.11 38-16 172.12 38-18 




28.2 5.04 Pindolol-d7 E2 
  




[M+H]+ 123.20 44-18 
- - 26.04 - - - - 
    E

















rac-Albuterol                           







































[M+H]+ 148.11 30-18 166.12 30-14 
21.01 3.12 Albuterol-d3 E1 0.49 1.05 
 E2
 
23.57 3.07 Albuterol-d3 E2 
  




[M+H]+ 151.15 28-18 
- - 21.17 - - - - 
   E2
 
- - 23.73 - - - - 
1
8 
rac-Clenbuterol                      







































[M+H]+ 203.09 30-16 132.00 30-30 
21.41 2.99 Clenbuterol-d9 E1 













[M+H]+ 204.13 36-18 
- - 21.33 - - - - 
    E2
 




Table S2. Sampling sites 
 Sampling site* Locality (Province) River Date Average flow (m3/s) 
% max 












GUA1 Villacarrillo (Jaén) Guadalquivir 03/11/2011 - - Agricultural activity: Olive trees  
 2 GUA2 Baeza (Jaén) Guadalquivir 03/11/2011 4.55 37% Near the source of the river  
 3 GUA3 Marmolejo (Jaén) Guadalquivir 09/11/2011 8.54 19% Near the source of the river  
   WWTP1 Córdoba (Córdoba) Treatment technology: Primary + Secondary (Activated sludge)   
 4 GUA4 Córdoba (Córdoba) Guadalquivir 09/11/2011 - - Downstream WWTP1  
 5 GUA5 Peñaflor (Sevilla) Guadalquivir 14/11/2011 10.59 44% Intermediate sampling site  
   WWTP2 Sevilla South (Sevilla) Treatment technology: Primary + Secondary (Activated sludge)   
 6 GUA6 Coria del Río (Sevilla) Guadalquivir 25/10/2011 - - Downstream WWTP2 and estuary  
 7 GUA7 Brazo del Este (Sevilla) Guadalquivir 28/10/2011 - - Estuary  
 8 GUA8 Lebrija (Sevilla) Guadalquivir 28/10/2011 - - Estuary  








BOR La Iruela (Jaén) Borosa 03/11/2011 - - Near the source of the river  
 2 GUAM Úbeda (Jaén) Guadiana Menor 03/11/2011 - - Before joining the Guadalquivir River  
 3 MAG Santa Elena (Jaén) Magaña 04/11/2011 - - Near the source of the river  
 4 GUAN Mengíbar (Jaén) Guadalbullón 03/11/2011 5.05 89% Before joining the Guadalquivir River  
 5 YEG Cardeña (Córdoba) Yeguas 09/11/2011 - - Zona contaminada por purines  
 6 GUAL Baena (Córdoba) Guadalmoral 02/11/2011 - - Agricultural activity: Olive trees  
 7 PIC Fuente Palmera (Córdoba) Picachos 14/11/2011 - - Agricultural activity: Orange trees  
 8 BEM Hornachuelos (Córdoba) Bembézar 02/11/2011 - - Near the source of the river  
 9 CAC Arenas del Rey (Granada) Cacín 18/11/2011 - - Near the source of the river  
   WWTP3 Loja (Granada) Treatment technology: Primary   
 10 GEN1 Loja (Granada) Genil 18/11/2011 0 - Downstream WWTP3  
 11 GEN2 Écija (Sevilla) Genil 14/11/2011 3.46 19% Before joining the Guadalquivir River  
 12 COR Carmona (Sevilla) Corbones 15/11/2011 2.95 86% Before joining the Guadalquivir River  
   WWTP4 Sevilla East (Sevilla) Treatment technology: Primary + Secondary (Activated sludge) + Tertiary   
 13 HER Alcalá del Río (Sevilla) Herreros 15/11/2011 - - Agricultural activity: Cereal  
   WWTP5 Morón de la Frontera (Sevilla) Treatment technology: Primary + Secondary (Activated sludge)   
 14 GUAA Morón de la Frontera (Sevilla) Guadaíra 15/11/2011 - - Downstream WWTP5 and military camp  
 15 GUAR Alnalcázar (Sevilla) Guadiamar 25/10/2011 0.06 5% Before joining the Guadalquivir River  
*: Abbreviations of the corresponding catchment river were chosen to name the sampling sites of SW 
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Table S3 . Concentrations and enantiomeric fractions of chiral drugs in the Guadalquivir River basin 
A) Analgesics and psychiatric drugs 
 
Sampling sites 
Concentration, ng L-1 (%RSD)  




EF / EFrel rac-Naproxen 
Fluoxetine     
EF / EFrel 
Norfluoxetine     
EF / EFrel 
 












1 GUA1 0.725 (67.9) 96.9 (33.3) 116 (35.9) 0.48/0.48 38.8 (54.7) bloq. n.d. - n.d. n.d. -  
 2 GUA2 5.48 (74.1) 346 (13.7) 422 (6.86) 0.48/0.48 169 (7.37) 0.212 (11.8) 0.0750 (66.7) 0.66/0.66 n.d. n.d. -  
 3 GUA3 3.60 (126) 185 (17.9) 225 (14.9) 0.48/0.48 186 (17.2) n.d. n.d. - n.d. n.d. -  
 
WWTP1 
Influent 481 (1.90) 1320 (54.1) 4827 (6.69) 0.25/0.25 4283 (9.14) 6.25 (0.00) 3.50 (10.1) 0.64/0.63 12.1 (141) 5.50 (141) 0.67/0.67  
 Effluent 353 (0.44) 669 (27.8) 921 (11.1) 0.46/0.46 572 (15.8) 10.9 (11.4) 6.25 (5.66) 0.60/0.62 0.875 (141) 0.375 (141) 0.69/0.69  
 4 GUA4 34.5 (9.19) 208 (8.65) 254 (3.54) 0.48/0.48 145 (14.1) 0.100 (0.00) 0.0333 (86.6) 0.63/0.64 n.d. n.d. -  
 5 GUA5 3.07 (86.7) 258 (6.23) 295 (6.42) 0.50/0.50 118 (9.90) n.d. n.d. - n.d. n.d. -  
 
WWTP2 
Influent 571 (0.140) 3055 (1.48) 3563 (10.2) 0.49/0.49 5143 (6.21) 11.4 (1.55) 6.12 (14.4) 0.67/0.64 6.25 (141) 9.50 (141) 0.38/0.38  
 Effluent 514 (7.12) 1392 (17.6) 16340 (8.32) 0.49/0.49 2008 (2.18) 6.75 (15.7) 3.62 (4.88) 0.63/0.64 0.875 (141) 1.13 (141) 0.42/0.42  
 6 GUA6 7.60 (31.6) 286 (3.67) 373 (4.92) 0.47/0.47 111 (6.17) 0.0250 (141) bloq. - n.d. n.d. -  
 7 GUA7 n.d. 253 (12.1) 322 (23.0) 0.48/0.48 275 (54.5) bloq. n.d. - n.d. n.d. -  
 8 GUA8 n.d. 141 (8.12) 181 (10.8) 0.47/0.47 91.7 (30.8) n.d. n.d. - n.d. n.d. -  








1 BOR 0.167 (173) 494 (7.07) 594 (4.06) 0.48/0.48 35.5 (5.32) n.d. n.d. - n.d. n.d. -  
 2 GUAM 0.200 (200) 155 (42.1) 179 (37.7) 0.49/0.49 22.8 (6.94) n.d. n.d. - n.d. n.d. -  
 3 MAG n.d. 174 (7.60) 222 (8.49) 0.47/0.47 67.5 (124) n.d. n.d. - n.d. n.d. -  
 4 GUAN 29.4 (86.6) 591 (19.5) 747 (8.88) 0.47/0.47 201 (15.1) 0.0333 (86.6) bloq. - n.d. n.d. -  
 5 YEG 6.63 (173) 141 (14.7) 183 (12.6) 0.47/0.47 141 (16.3) 0.0333 (86.6) bloq. - n.d. n.d. -  
 6 GUAL 0.450 (128) 143 (28.6) 168 (37.8) 0.49/0.49 125 (89.4) n.d. n.d. - n.d. n.d. -  
 7 PIC 0.667 (87.9) 160 (19.3) 194 (28.4) 0.49/0.49 69.7 (8.24) n.d. n.d. - n.d. n.d. -  
 8 BEM 0.433 (173) 180 (12.0) 237 (3.57) 0.46/0.46 63.5 (32.5) n.d. n.d. - n.d. n.d. -  
 9 CAC 0.100 (173) 31.2 (35.6) 37.7 (36.3) 0.49/0.49 1.87 (134) n.d. n.d. - n.d. n.d. -  
 
WWTP3 
Influent 16.3 (101) 411 (30.6) 501 (24.3) 0.48/0.48 122 (1.45) 0.750 (0.00) 0.500 (0.00) 0.61/0.60 0.125 (141) n.d. -  
 Effluent 1.75 (15.2) 226 (17.0) 262 (6.21) 0.49/0.49 33.5 (63.3) 0.375 (47.1) 0.250 (0.00) 0.62/0.60 n.d. n.d. -  
 10 GEN1 12.6 (2.82) 354 (6.60) 412 (4.96) 0.49/0.49 339 (6.55) 0.275 (12.9) 0.100 (0.00) 0.67/0.68 0.400 (141) 0.100 (141) 0.76/0.76  
 11 GEN2 n.d. 289 (104) 424 (20.2) 0.30/0.30 266 (11.2) n.d. bloq. - n.d. n.d. -  




Influent 366 (5.50) 4390 (39.2) 6201 (10.9) 0.44/0.44 5511 (1.01) 4.87 (3.63) 2.87 (18.4) 0.71/0.61 5.38 (141) 12.0 (141) 0.29/0.29  
 Effluent 296 (3.38) 1111 (13.3) 1174 (7.14) 0.51/0.51 300 (2.12) 5.75 (0.00) 2.75 (0.00) 0.66/0.66 0.750 (141) 0.125 (141) 0.81/0.81  
 13 HER n.d. 821 (50.2) 1043 (51.8) 0.46/0.46 221 (29.6) bloq. n.d. - n.d. n.d. -  
 
WWTP5 
Influent 616 (6.29) 3823 (3.99) 4703 (11.6) 0.48/0.48 5307 (10.3) 7.75 (4.56) 3.87 (4.56) 0.65/0.65 8.63 (141) 7.50 (141) 0.51/0.51  
 Effluent 242 (3.62) 1094 (6.82) 1222 (2.33) 0.50/0.50 219 (7.92) 11.2 (9.43) 5.87 (3.00) 0.64/0.64 n.d. n.d. -  
 14 GUAA 7.45 (23.7) 253 (11.3) 312 (0.623) 0.48/0.48 243 (10.3) 0.0500 (0.00) bloq. - n.d. n.d. -  
 15 GUAR 0.900 (173) 777 (21.6) 1024 (7.42) 0.46/0.46 61.1 (140) bloq. n.d. - n.d. n.d. -  
                
 
B) Cardiovascular drugs I 
              
 
Sampling sites 
Concentration, ng L-1 (%RSD)  
 Cardiovascular drugs and transformation products (9)  
 Atenolol 
EF / EFrel 
Sotalol 
EF / EFrel 
Metoprolol 
EF / EFrel 
 












1 GUA1 2.30 (5.89) 2.21 (2.84) 0.50/0.50 n.d. n.d. - 0.0125 (200) n.d.    
 2 GUA2 11.8 (4.25) 11.4 (2.77) 0.50/0.50 0.675 (66.9) 0.612 (67.1) 0.44/0.49 0.288 (8.70) 0.300 (68.0) 0.59/0.47  
 3 GUA3 18.3 (3.42) 13.0 (3.05) 0.42/0.42 0.467 (87.3) 0.467 (87.3) 0.47/0.50 0.733 (10.4) 0.700 (12.4) 0.56/0.50  
 
W W TP1 
Influent 445 (0.0398) 437 (1.17) 0.49/0.50 15.13 (1.17) 15.1 (3.51) 0.52/0.51 18.5 (1.91) 20.2 (1.75) 0.54/0.48  
 Effluent 232 (1.14) 176 (2.21) 0.44/0.43 14.63 (3.63) 14.9 (1.19) 0.46/0.50 15.5 (0.00) 20.0 (3.54) 0.48/0.44  
 4 GUA4 48.2 (2.03) 47.2 (0.922) 0.51/0.50 2.12 (3.61) 2.32 (2.49) 0.45/0.48 2.07 (5.59) 1.97 (10.3) 0.61/0.51  
 5 GUA5 15.2 (5.89) 13.4 (4.83) 0.49/0.48 1.00 (0.00) 0.967 (7.90) 0.47/0.50 0.700 (7.14) 0.700 (14.3) 0.59/0.50  
 
W W TP2 
Influent 1317 (5.03) 1315 (0.309) 0.49/0.50 45.7 (0.00) 47.9 (3.32) 0.51/0.50 36.6 (4.34) 39.6 (6.69) 0.63/0.49  
 Effluent 745 (1.33) 730 (0.315) 0.51/0.50 37.13 (2.38) 32.2 (4.39) 0.48/0.54 8.88 (1.99) 11.9 (4.47) 0.55/0.43  
 6 GUA6 36.9 (3.16) 35.1 (4.42) 0.49/0.49 1.38 (2.57) 1.32 (2.67) 0.47/0.51 0.925 (3.82) 1.00 (7.07) 0.52/0.48  
 7 GUA7 15.0 (3.98) 13.9 (8.14) 0.49/0.49 1.22 (2.37) 1.50 (5.77) 0.42/0.45 1.67 (9.17) 1.78 (9.01) 0.57/0.49  
 8 GUA8 5.92 (4.17) 3.58 (4.48) 0.39/0.38 0.383 (86.8) 0.217 (87.4) 0.52/0.60 0.0667 (86.6) 0.0167 (173) 0.66/0.51  








1 BOR 1.78 (8.09) 1.03 (86.7) 0.48/0.48 0.533 (5.41) 0.567 (5.09) 0.47/0.48 bloq. bloq. -  
 2 GUAM 2.65 (5.34) 2.44 (2.58) 0.49/0.49 0.787 (3.17) 0.850 (6.79) 0.40/0.48 0.212 (11.8) 0.212 (67.6) 0.60/0.45  
 3 MAG n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 4 GUAN 56.0 (3.49) 50.3 (2.14) 0.470.48 0.667 (8.66) 0.633 (4.56) 0.45/0.51 1.40 (3.57) 1.47 (5.21) 0.57/0.49  
 5 YEG 5.60 (3.22) 4.63 (3.79) 0.47/0.46 n.d. n.d. - 0.200 (25.0) 0.217 (13.3) 0.48/0.48  
 6 GUAL 1.04 (68.1) 0.94 (66.8) 0.48/0.47 1.58 (6.61) 1.85 (2.21) 0.39/0.46 0.262 (18.2) 0.388 (28.6) 0.58/0.42  
 11 
 7 PIC 4.50 (6.19) 3.70 (5.89) 0.47/0.46 n.d. n.d. - n.d. n.d. -  
 8 BEM 0.167 (173) 0.150 (173) 0.48/0.48 0.333 (86.6) 0.700 (0.00) 0.38/0.41 n.d. 0.0333 (86.6) -  
 9 CAC n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 
W W TP3 
Influent 53.0 (0.667) 53.5 (4.63) 0.50/0.50 n.d. n.d. - bloq. 0.375 (47.1) -  
 Effluent 8.50 (4.16) 7.88 (2.24) 0.48/0.48 n.d. n.d. - n.d. n.d. -  
 10 GEN1 90.6 (0.273) 88.4 (4.24) 0.50/0.50 3.15 (0.00) 3.40 (0.00) 0.44/0.49 3.05 (4.64) 3.45 (2.05) 0.49/0.47  
 11 GEN2 19.7 (8.88) 18.5 (7.01) 0.55/0.49 0.637 (67.9) 0.762 (67.6) 0.41/0.45 0.450 (15.7) bloq. -  
 12 COR 4.84 (5.62) 4.06 (5.98) 0.47/0.46 0.725 (67.9) 1.08 (8.06) 0.39/0.46 0.162 (68.2) bloq. -  
 
W W TP4 
Influent 556 (3.69) 557 (4.73) 0.49/0.50 23.0 (0.00) 23.8 (1.49) 0.46/0.50 38.4 (5.07) 41.2 (3.43) 0.69/0.49  
 Effluent 218 (1.05) 171 (2.47) 0.45/0.44 20.9 (2.54) 27.5 (5.14) 0.37/0.44 29.4 (1.81) 34.5 (3.07) 0.63/0.47  
 13 HER 9.67 (4.75) 8.20 (0.862) 0.48/0.47 n.d. n.d. - n.d. 0.0250 (141) -  
 
W W TP5 
Influent 859 (2.53) 850 (1.58) 0.57/0.50 60.6 (1.46) 62.7 (1.13) 0.48/0.50 66.0 (2.68) 71.8 (0.493) 0.58/0.49  
 Effluent 342 (2.12) 300 (1.47) 0.47/0.47 57.0 (7.44) 71.4 (2.23) 0.41/0.45 72.13 (2.21) 85.4 (1.45) 0.51/0.46  
 14 GUAA 33.8 (2.09) 29.6 (2.03) 0.47/0.47 5.38 (0.658) 7.58 (1.40) 0.40/0.42 9.58 (1.85) 10.2 (1.74) 0.51/0.49  
 15 GUAR 0.0833 (173) bloq. - n.d. n.d. - n.d. n.d. -  
              
 
C) Cardiovascular drugs II 
 
Sampling sites 
Concentration, ng L-1 (%RSD)  
 Cardiovascular drugs and transformation products (9)  
 Propranolol 
EF / EFrel 
4OH propranolol  
EF / EFrel 
Timolol 
EF / EFrel 
 












1 GUA1 bloq. bloq.   n.d. n.d. - bloq. n.d.    
 2 GUA2 1.75 (7.00) 1.3-3 (8.98) 0.55/0.43 n.d. n.d. - 0.0333 (150) n.d. 0/0  
 3 GUA3 0.700 (7.14) 0.433 (6.66) 0.46/0.38 n.d. n.d. - 0.100 (100) n.d. 0/0  
 
W W TP1 
Influent 30.2 (5.84) 25.9 (0.683) 0.61/0.46 n.d. n.d. - 3.50 (40.4) n.d. 0/0  
 Effluent 46.1 (0.383) 38.0 (1.86) 0.55/0.45 n.d. n.d. - 3.13 (39.6) n.d. 0/0  
 4 GUA4 4.42 (2.85) 3.17 (3.97) 0.56/0.41 n.d. n.d. - 0.300 (100) n.d. 0/0  
 5 GUA5 1.32 (5.80) 0.900 (9.62) 0.54/0.40 n.d. n.d. - 0.100 (100) n.d. 0/0  
 
W W TP2 
Influent 32.4 (6.01) 23.3 (1.52) 0.65/0.41 n.d. n.d. - 6.25 (50.9) n.d. 0/0  
 Effluent 28.8 (9.84) 19.1 (0.924) 0.58/0.40 n.d. n.d. - 5.13 (37.9) n.d. 0/0  
 6 GUA6 1.22 (14.4) 0.750 (0.00) 0.49/0.38 n.d. n.d. - 0.150 (47.1) n.d. 0/0  
 7 GUA7 0.15 (173) 0.300 (88.2) 0.58/0.46 n.d. n.d. - n.d. n.d. -  
 12 
 8 GUA8 n.d. n.d. - n.d. n.d. - n.d. n.d. -  








1 BOR 0.0667 (86.6) 0.0500 (100) 0.42/0.41 n.d. n.d. - bloq. n.d. -  
 2 GUAM 0.0500 (200) 0.0250 (200) 0.50/0.46 n.d. n.d. - bloq. n.d. -  
 3 MAG n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 4 GUAN 1.67 (8.66) 1.10 (0.00) 0.52/0.39 n.d. n.d. - 0.500 (52.0) n.d. 0/0  
 5 YEG 0.617 (4.68) 0.483 (5.97) 0.45/0.43 n.d. n.d. - bloq. n.d. -  
 6 GUAL bloq. 0.0875 (118) - n.d. n.d. - bloq. n.d. -  
 7 PIC 0.0500 (0.00) bloq. - n.d. n.d. - bloq. n.d. -  
 8 BEM 0.0333 (173) n.d. - n.d. n.d. - bloq. n.d. -  
 9 CAC n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 
W W TP3 
Influent 0.250 (0.00) 0.250 (0.00) 0.37/0.37 n.d. n.d. - bloq. n.d. -  
 Effluent n.d. bloq. - n.d. n.d. - bloq. n.d. -  
 10 GEN1 2.30 (6.15) 1.73 (2.05) 0.51/0.42 n.d. n.d. - 0.525 (47.1) n.d. 0/0  
 11 GEN2 0.225 (117) 0.200 (115) 0.58/0.62 n.d. n.d. - 0.0250 (200) n.d. 0/0  
 12 COR bloq. bloq. - n.d. n.d. - bloq. n.d. -  
 
W W TP4 
Influent 17.5 (10.1) 10.3 (3.45) 0.61/0.37 n.d. n.d. - 3.38 (47.1) n.d. 0/0  
 Effluent 14.9 (1.19) 11.13 (1.59) 0.60/0.42 n.d. n.d. - 2.25 (47.1) n.d. 0/0  
 13 HER 0.0250 (141) 0.125 (28.3) 0.72/0.66 n.d. n.d. - n.d. n.d. -  
 
W W TP5 
Influent 21.6 (7.36) 15.0 (0.00) 0.62/0.40 n.d. n.d. - 5.00 (42.4) n.d. 0/0  
 Effluent 14.5 (2.44) 9.62 (1.84) 0.54/0.39 n.d. n.d. - 3.88 (41.0) n.d. 0/0  
 14 GUAA 1.18 (9.03) 0.825 (4.29) 0.48/0.40 n.d. n.d. - 0.450 (47.1) n.d. 0/0  
 15 GUAR 0.0167 (173) n.d. - n.d. n.d. - n.d. n.d. -  










D) Cardiovascular drugs III 
 
Sampling sites 
Concentration, ng L-1 (%RSD)  
 Cardiovascular drugs and transformation products (9)  
 Betaxolol  
EF / EFrel 
Carazolol 
EF / EFrel 
Pindolol   
EF / EFrel 
 













1 GUA1 n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 2 GUA2 n.d. n.d. - n.d. n.d. - bloq. n.d. -  
 3 GUA3 n.d. n.d. - n.d. n.d. - bloq. n.d. -  
 W W TP1 
Influent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 Effluent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 4 GUA4 n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 5 GUA5 n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 W W TP2 
Influent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 Effluent n.d. n.d. - n.d. n.d. - n.d. bloq. -  
 6 GUA6 n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 7 GUA7 n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 8 GUA8 n.d. n.d. - n.d. n.d. - n.d. n.d. -  








1 BOR n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 2 GUAM n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 3 MAG n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 4 GUAN n.d. n.d. - n.d. n.d. - bloq. n.d. -  
 5 YEG n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 6 GUAL n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 7 PIC n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 8 BEM n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 9 CAC n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 W W TP3 
Influent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 Effluent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 10 GEN1 n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 11 GEN2 n.d. n.d. - n.d. n.d. - 0.0125 (200) n.d. -  
 12 COR n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 14 
 W W TP4 
Influent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 Effluent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 13 HER n.d. n.d. - n.d. n.d. - n.d. bloq. -  
 W W TP5 
Influent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 Effluent n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 14 GUAA n.d. n.d. - n.d. n.d. - n.d. n.d. -  
 15 GUAR n.d. n.d. - n.d. n.d. - n.d. n.d. -  
              
 
E) β-agonists and antibiotics 
 
 
Concentration, ng L-1 (%RSD) Concentration, ng L-1 (%RSD)  
 β-agonists (2) Antibiotics (1)  
 Albuterol 
EF / EFrel 
Clenbuterol 
EF / EFrel rac-Flumequine 
 












1 GUA1 n.d. n.d.  n.d. n.d.   n.d.  
 2 GUA2 n.d. bloq.  n.d. n.d.   n.d.  
 3 GUA3 0.0667 (173) 0.0833 (173) 0.24/0.25 n.d. n.d.   n.d.  
 
W W TP1 
Influent 3.50 (20.2) 4.75 (7.44) 0.23/0.43 n.d. n.d.   bloq.  
 Effluent 2.50 (0.00) 4.00 (8.84) 0.35/0.38 n.d. n.d.   n.d.  
 4 GUA4 0.433 (6.66) 0.683 (11.2) 0.38/0.39 n.d. n.d.   n.d.  
 5 GUA5 bloq. 0.100 (173)  n.d. n.d.   n.d.  
 
W W TP2 
Influent 4.75 (7.44) 8.50 (0.00) 0.35/0.36 n.d. n.d.   n.d.  
 Effluent 3.88 (4.56) 6.63 (2.67) 0.36/0.36 n.d. n.d.   n.d.  
 6 GUA6 0.325 (10.9) 0.475 (7.44) 0.38/0.40 n.d. n.d.   n.d.  
 7 GUA7 bloq. 0.200 (90.1)  n.d. n.d.   n.d.  
 8 GUA8 n.d. 0.0500 (173)  n.d. n.d.   bloq.  








1 BOR n.d. n.d.  n.d. n.d.   bloq.  
 2 GUAM n.d. n.d.  n.d. n.d.   n.d.  
 3 MAG n.d. n.d.  n.d. n.d.   n.d.  
 4 GUAN 0.367 (7.87) 0.550 (0.00) 0.39/0.40 n.d. n.d.   n.d.  
 5 YEG n.d. 0.0333 (173)  n.d. n.d.   n.d.  
 6 GUAL bloq. 0.150 (66.7)  n.d. n.d.   n.d.  
 15 
 7 PIC n.d. n.d.  n.d. n.d.   n.d.  
 8 BEM n.d. n.d.  n.d. n.d.   n.d.  
 9 CAC n.d. n.d.  n.d. n.d.   n.d.  
 
W W TP3 
Influent 0.125 (141) 0.375 (47.1) 0.36/0.36 n.d. n.d.   n.d.  
 Effluent n.d. 0.125 (141)  n.d. n.d.   n.d.  
 10 GEN1 0.400 (0.00) 0.725 (4.88) 0.35/0.37 n.d. n.d.   3.05 (2.32)  
 11 GEN2 0.0625 (200) 0.325 (72.7) 0.60/0.37 n.d. n.d.   n.d.  
 12 COR n.d. bloq.  n.d. n.d.   n.d.  
 
W W TP4 
Influent 3.63 (4.88) 6.25 (0.00) 0.33/0.37 n.d. n.d.   n.d.  
 Effluent 3.25 (0.00) 6.00 (0.00) 0.34/0.34 n.d. n.d.   n.d.  
 13 HER bloq. 0.0500 (141)  n.d. n.d.   n.d.  
 
W W TP5 
Influent 4.38 (4.04) 7.75 (4.56) 0.33/0.36 n.d. n.d.   n.d.  
 Effluent 4.50 (0.00) 8.62 (2.05) 0.35/0.34 n.d. n.d.   n.d.  
 14 GUAA 0.650 (0.00) 1.20 (0.00) 0.33/0.35 n.d. n.d.   n.d.  
 15 GUAR bloq. 0.0333 (173)   n.d. n.d.   n.d.  
            
 
